Grants paid by The Barth Syndrome Foundation
EIN 22-3755704 · Larchmont, NY · Form 990, Schedule I · NTEE T30
The Barth Syndrome Foundation of Larchmont, NY (EIN 22-3755704) reported 32 grants paid totaling $1,875,952 to 24 recipients in tax years 2018–2025, on Form 990, Schedule I. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.
Grants paid
$1,875,952
32 grants
Recipients
24
distinct organizations
Tax years
2018–2025
8 filings in the corpus
By tax year
| Tax year | Grants paid | Amount paid | Approved for future |
|---|---|---|---|
| 2018 | 4 | $154,250 | — |
| 2019 | 5 | $336,917 | — |
| 2020 | 5 | $201,587 | — |
| 2021 | 3 | $184,189 | — |
| 2022 | 4 | $302,773 | — |
| 2023 | 3 | $128,032 | — |
| 2024 | 4 | $235,746 | — |
| 2025 | 4 | $332,458 | — |
Top recipients
The 24 recipients receiving the most from The Barth Syndrome Foundation, by grants paid, out of 24 distinct recipients.
| Recipient | Match | Location | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| Boston Children's Hospital | U | Boston, MA | 4 | $299,967 | 2023 |
| New York University 13-5562308 | A | New York, NY | 3 | $184,580 | 2025 |
| Boston Childrens Hospital 04-2774441 | A | Boston, MA | 1 | $130,507 | 2025 |
| Texas Health Center | U | Austin, TX | 1 | $100,000 | 2022 |
| New York University School of Medicine 37-1592643 | C | New York, NY | 2 | $100,000 | 2019 |
| University of California Regents | U | Los Angeles, CA | 1 | $100,000 | 2019 |
| Wayne State University 38-3555142 | A | Detroit, MI | 2 | $100,000 | 2019 |
| Wake Forest University Health Sciences | U | Winstonsalem, NC | 1 | $100,000 | 2021 |
| Duke University 56-0532129 | A | Durham, NC | 1 | $99,519 | 2024 |
| Nyu Registry Arrhythmia Study | U | New York, NY | 2 | $94,078 | 2023 |
| Colorado State University | U | Fort Collins, CO | 1 | $82,400 | 2022 |
| Indiana University 35-6001673 | A | Bloomington, IN | 1 | $80,000 | 2025 |
| Texas A&m 87-2371687 | B | College Station, TX | 1 | $50,000 | 2020 |
| Massachusetts General Hospital 04-1564655 | C | Boston, MA | 1 | $50,000 | 2019 |
| Virginia Commonwealth University | U | Richmond, VA | 1 | $50,000 | 2021 |
| Stony Brook University | U | Stony Brook, NY | 1 | $50,000 | 2020 |
| University of Connecticut 52-1538517 | B | Storrs, CT | 1 | $50,000 | 2020 |
| Uc Boulder 84-6000555 | A | Boulder, CO | 1 | $40,000 | 2024 |
| Adelphi Values | U | Boston, MA | 1 | $34,250 | 2018 |
| American Heart Association 13-5613797 | B | Dallas, TX | 1 | $34,189 | 2021 |
| University of Pittsburgh 25-0965591 | A | Pittsburgh, PA | 1 | $33,598 | 2025 |
| American Heart Association | U | New York, NY | 1 | $16,277 | 2023 |
| (name not stated) | U | 1 | $0 | 2018 | |
| Duke University 22-3114978 | B | Durham, NC | 1 | -$3,413 | 2020 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Every grant
All 32 grant rows this organization reported, most recent first.
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2025 | Boston Childrens Hospital Boston, MA | A | $130,507 | paid | GENE THERAPY | 202621949349301537 |
| 2025 | New York University New York, NY | A | $88,353 | paid | ARRHYTHMIA PROJECT | 202621949349301537 |
| 2025 | Indiana University Bloomington, IN | A | $80,000 | paid | ROLE OF P53 PATHWAY IN BARTH SYNDROME PATIENT-TAILORED MOUSE ALLELE | 202621949349301537 |
| 2025 | University of Pittsburgh Pittsburgh, PA | A | $33,598 | paid | ARRHYTHMIA PROJECT | 202621949349301537 |
| 2024 | Duke University Durham, NC | A | $99,519 | paid | CARDIAC AND SKELETAL MUSCLE MYOFILAMENT ACTIVATORS FOR THE TREATMENT OF BARTH SYNDROME | 202511899349301801 |
| 2024 | New York University New York, NY | A | $75,000 | paid | MECHANISM OF CARDIOLIPIN REMODELING BY TAFAZZIN | 202511899349301801 |
| 2024 | Uc Boulder Boulder, CO | A | $40,000 | paid | INVESTIGATING THE MOLECULAR BASIS FOR THE IMPAIRED MITOCHONDRIAL DYNAMICS IN BARTH SYNDROME | 202511899349301801 |
| 2024 | New York University New York, NY | A | $21,227 | paid | ARRHYTHMIA PROJECT | 202511899349301801 |
| 2023 | Boston Children's Hospital Boston, MA | U | $69,300 | paid | OPTIMIZATION OF BARTH SYNDROME GENE THERAPY | 202421659349301542 |
| 2023 | Nyu Registry Arrhythmia Study New York, NY | U | $42,455 | paid | ACTIVATING PYRUVATE DEHYDROGENASE COMPLEX TO IMPROVE BARTH SYNDROMECARDIAC FUNCTION | 202421659349301542 |
| 2023 | American Heart Association New York, NY | U | $16,277 | paid | HEART DISEASE, STROKE, AND CARDIOVASCULAR HEALTH | 202421659349301542 |
| 2022 | Texas Health Center Austin, TX | U | $100,000 | paid | ALCAT1 AS A NOVEL TARGET FOR THE TREATMENT OF CARDIOMYOPATHY IN BARTH SYNDROME | 202342149349300909 |
| 2022 | Colorado State University Fort Collins, CO | U | $82,400 | paid | FEEDING THE STARVING HEART IN BARTH SYNDROME | 202342149349300909 |
| 2022 | Boston Children's Hospital Boston, MA | U | $68,750 | paid | OPTIMIZATION OF BARTH SYNDROME GENE THERAPY | 202342149349300909 |
| 2022 | Nyu Registry Arrhythmia Study New York, NY | U | $51,623 | paid | ACTIVATING PYRUVATE DEHYDROGENASE COMPLEX TO IMPROVE BARTH SYNDROMECARDIAC FUNCTION | 202342149349300909 |
| 2021 | Wake Forest University Health Sciences Winstonsalem, NC | U | $100,000 | paid | ACTIVATING PYRUVATE DEHYDROGENASE COMPLEX TO IMPROVE BARTH SYNDROMECARDIAC FUNCTION | 202241949349301764 |
| 2021 | Virginia Commonwealth University Richmond, VA | U | $50,000 | paid | "WHAT IS BARTH TIRED?": A MIXED METHODS APPROACH TO QUALIFYING AND QUANTIFYING FATIGUE IN MALES WITH BARTH SYNDROME | 202241949349301764 |
| 2021 | American Heart Association Dallas, TX | B | $34,189 | paid | ROLE OF CARDIOLIPIN IN CARDIAC ADP/ATP TRANSLOCATOR ACTIVITY | 202241949349301764 |
| 2020 | Boston Children's Hospital Boston, MA | U | $55,000 | paid | ESSENTIAL ACTIVITIES OF TAFAZZIN THAT ARE INDEPENDENT OF CARDIOLIPIN REMODELING | 202122249349300702 |
| 2020 | Stony Brook University Stony Brook, NY | U | $50,000 | paid | STRUCTURAL AND BIOPHYSICAL STUDIES OF TAFAZZIN | 202122249349300702 |
| 2020 | Texas A&m College Station, TX | B | $50,000 | paid | CARDIOLIPIN REQUIREMENT FOR MITOCHONDRIAL CALCIUM IMPORT | 202122249349300702 |
| 2020 | University of Connecticut Storrs, CT | B | $50,000 | paid | DEVELOPMENT OF MITOCHONDRIA-TARGETED PEPTIDE COMPOUNDS AS BARTH SYNDROME THERAPEUTICS | 202122249349300702 |
| 2020 | Duke University Durham, NC | B | -$3,413 | paid | REFUND RECEIVED OF PRIOR YEAR GRANT | 202122249349300702 |
| 2019 | Boston Children's Hospital Boston, MA | U | $106,917 | paid | DISCOVERY OF GENETIC MODIFIERS OF BARTH SYNDROME | 202021629349300107 |
| 2019 | University of California Regents Los Angeles, CA | U | $100,000 | paid | DEUTERATED POLYUNSATURATED FATTY ACIDS AS PROTECTIVE THERAPY IN THE TREATMENT OF BARTH SYNDROME | 202021629349300107 |
| 2019 | Wayne State University Detroit, MI | A | $50,000 | paid | SUPPLEMENTATION OF CRITICAL METABOLITES IMPROVES TCA CYCLE FUNCTION AND VIABILITY OF TAFAZZIN-DEFICIENT CELLSSUPPLEMENTATION OF CRITICAL METABOLITES IMPROVES TCA CYCLE FUNCTION AND VIABILITY OF TAFAZZIN-DEFICIENT CELLSSUPPLEMENTATION OF CRITICAL METABOLITES IMPROVES TCA CYCLE FUNCTION AND VIABILITY OF TAFAZZIN-DEFICIENT CELLSSUPPLEMENTATION OF CRITICAL METABOLITES IMPROVES TCA CYCLE FUNCTION AND VIABILITY OF TAFAZZIN-DEFICIENT CELLS | 202021629349300107 |
| 2019 | Massachusetts General Hospital Boston, MA | C | $50,000 | paid | ADDRESS THE MECHANISM OF NEUTROPENIA IN PATIENTS WITH BARTH SYNDROME | 202021629349300107 |
| 2019 | New York University School of Medicine New York, NY | C | $30,000 | paid | CHARACTERIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS IN BARTH SYNDROME | 202021629349300107 |
| 2018 | New York University School of Medicine New York, NY | C | $70,000 | paid | PRENATAL CARDIAC PHENOTYPE AS A PLATFORM FOR TESTING BARTH SYNDROME THERAPIES | 201901349349301105 |
| 2018 | Wayne State University Detroit, MI | A | $50,000 | paid | CARDIOLIPIN ACTIVATES PYRUVATE DEHYDROGENARE (PDH) - A POTENTIAL NEW TARGET FOR TREATMENT OF BARTH SYNDROME | 201901349349301105 |
| 2018 | Adelphi Values Boston, MA | U | $34,250 | paid | STUDY THE HEALTH OF A SUB-POPULATION (OLDER INDIVIDUALS AFFECTED WITH BTHS) WITHIN BSF'S COMMUNITY | 201901349349301105 |
| 2018 | (name not stated) | U | $0 | paid | CARDIOLIPIN ACTIVATES PYRUVATE DEHYDROGENARE (PDH) - A POTENTIAL NEW TARGET FOR TREATMENT OF BARTH SYNDROME | 201901349349301105 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Source filings
Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.
| Form | Tax year | Period end | Filed | Schema | IRS OBJECT_ID |
|---|---|---|---|---|---|
| 990 | 2025 | 2025-12-31 | not stated | 2025v4.2 | 202621949349301537 |
| 990 | 2024 | 2024-12-31 | not stated | 2024v5.2 | 202511899349301801 |
| 990 | 2023 | 2023-12-31 | not stated | 2023v5.0 | 202421659349301542 |
| 990 | 2022 | 2022-12-31 | not stated | 2022v5.0 | 202342149349300909 |
| 990 | 2021 | 2021-12-31 | not stated | 2021v4.2 | 202241949349301764 |
| 990 | 2020 | 2020-12-31 | not stated | 2020v4.1 | 202122249349300702 |
| 990 | 2019 | 2019-12-31 | not stated | 2019v5.1 | 202021629349300107 |
| 990 | 2018 | 2018-12-31 | not stated | 2018v3.1 | 201901349349301105 |
Derived from IRS Form 990 e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/223755704.json.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.